What is the difference between LEVALBUTEROL TARTRATE and SALMETEROL XINAFOATE?

LEVALBUTEROL TARTRATE and SALMETEROL XINAFOATE are both Beta-2 Agonist Bronchodilators, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Can LEVALBUTEROL TARTRATE and SALMETEROL XINAFOATE be used for the same conditions?

Both medications are prescribed for overlapping indications including See full prescribing information. Always verify with your prescriber and the current FDA label before switching.

Is Levalbuterol tartrate HFA inhalation the same as SEREVENT DISKUS?

No. Levalbuterol tartrate HFA inhalation (LEVALBUTEROL TARTRATE) and SEREVENT DISKUS (SALMETEROL XINAFOATE) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, LEVALBUTEROL TARTRATE or SALMETEROL XINAFOATE?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from LEVALBUTEROL TARTRATE to SALMETEROL XINAFOATE?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

LEVALBUTEROL TARTRATE vs SALMETEROL XINAFOATE

Compare LEVALBUTEROL TARTRATE (Levalbuterol tartrate HFA inhalation) and SALMETEROL XINAFOATE (SEREVENT DISKUS) — clinical data, side effects, and patient experiences.

LEVALBUTEROL TARTRATE

Levalbuterol tartrate HFA inhalation · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular con...

Approved for

See full prescribing information

OralTablet

SALMETEROL XINAFOATE

SEREVENT DISKUS · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although ...

Approved for

including patients with symptoms of nocturnal asthma. LABA

such as salmeterol

the active ingredient in SEREVENT DISKUS

appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be assured

Oral, Respiratory (inhalation)Tablet

Quick Comparison

LEVALBUTEROL TARTRATESALMETEROL XINAFOATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral

Oral, Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVALBUTEROL TARTRATE

Shortness of Breath

>10%

Fatigue

1-10%

Cough

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Headache

1-10%

Diarrhea

0.1-1%

Dizziness

0.1-1%

SALMETEROL XINAFOATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

1-10%

General Unwellness

1-10%

Headache

0.1-1%

Nausea

0.1-1%

Dizziness

0.1-1%

FDA Warnings

LEVALBUTEROL TARTRATE

No specific warnings

SALMETEROL XINAFOATE

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations
3 ) • Do not use in combination with an additional medicine containing a LABA because of risk of overdose
1 Asthma-Related Death LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death
When LABA are used in fixed - dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Clinical Trial Data

No head-to-head clinical studies found for LEVALBUTEROL TARTRATE vs SALMETEROL XINAFOATE.

LEVALBUTEROL TARTRATE vs SALMETEROL XINAFOATE: What You Should Know

Key Differences

Both LEVALBUTEROL TARTRATE and SALMETEROL XINAFOATE belong to the Beta-2 Agonist Bronchodilator class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. LEVALBUTEROL TARTRATE is administered via Oral, whereas SALMETEROL XINAFOATE uses Oral or Respiratory (inhalation). Route of administration can affect onset of action and patient adherence.

Safety Considerations

SALMETEROL XINAFOATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

FORMOTEROL FUMARATE vs SALMETEROL XINAFOATE→ALBUTEROL vs SALMETEROL XINAFOATE→LEVALBUTEROL HYDROCHLORIDE vs SALMETEROL XINAFOATE→FORMOTEROL FUMARATE DIHYDRATE vs SALMETEROL XINAFOATE→SALMETEROL XINAFOATE vs TIOTROPIUM BROMIDE AND OLODATEROL→FLUTICASONE PROPIONATE AND SALMETEROL vs SALMETEROL XINAFOATE→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

LEVALBUTEROL TARTRATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
SALMETEROL XINAFOATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

LEVALBUTEROL TARTRATE vs SALMETEROL XINAFOATE

Compare LEVALBUTEROL TARTRATE (Levalbuterol tartrate HFA inhalation) and SALMETEROL XINAFOATE (SEREVENT DISKUS) — clinical data, side effects, and patient experiences.

LEVALBUTEROL TARTRATE

Levalbuterol tartrate HFA inhalation · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Activation of beta 2 -adrenergic receptors on airway smooth muscle leads to the activation of adenylate cyclase and to an increase in the intracellular con...

Approved for

See full prescribing information

OralTablet

SALMETEROL XINAFOATE

SEREVENT DISKUS · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although ...

Approved for

including patients with symptoms of nocturnal asthma. LABA

such as salmeterol

the active ingredient in SEREVENT DISKUS

appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be assured

Oral, Respiratory (inhalation)Tablet

Quick Comparison

LEVALBUTEROL TARTRATESALMETEROL XINAFOATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral

Oral, Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

LEVALBUTEROL TARTRATE

Shortness of Breath

>10%

Fatigue

1-10%

Cough

1-10%

Drug Not Working

1-10%

Nausea

1-10%

Headache

1-10%

Diarrhea

0.1-1%

Dizziness

0.1-1%

SALMETEROL XINAFOATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

1-10%

General Unwellness

1-10%

Headache

0.1-1%

Nausea

0.1-1%

Dizziness

0.1-1%

FDA Warnings

LEVALBUTEROL TARTRATE

No specific warnings

SALMETEROL XINAFOATE

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations
3 ) • Do not use in combination with an additional medicine containing a LABA because of risk of overdose
1 Asthma-Related Death LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death
When LABA are used in fixed - dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Clinical Trial Data

No head-to-head clinical studies found for LEVALBUTEROL TARTRATE vs SALMETEROL XINAFOATE.

LEVALBUTEROL TARTRATE vs SALMETEROL XINAFOATE: What You Should Know

Key Differences

Safety Considerations

SALMETEROL XINAFOATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

LEVALBUTEROL TARTRATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov
SALMETEROL XINAFOATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov